{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:16:14Z","timestamp":1773922574635,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Drug Investig."],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1007\/bf03256934","type":"journal-article","created":{"date-parts":[[2013,3,2]],"date-time":"2013-03-02T20:37:05Z","timestamp":1362256625000},"page":"351-355","source":"Crossref","is-referenced-by-count":12,"title":["Safe Administration of Celecoxib to a Patient with Repeated Episodes of Nephrotic Syndrome Induced by NSAIDs"],"prefix":"10.1007","volume":"31","author":[{"given":"Karlo","family":"Mihovilovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danica","family":"Ljubanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mladen","family":"Knotek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,24]]},"reference":[{"issue":"1","key":"BF03256934_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1874467210902010001","volume":"2","author":"M. Hamza","year":"2009","unstructured":"Hamza M, Dionne RA. Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition. Curr Mol Pharmacol 2009; 2(1): 1\u201314","journal-title":"Curr Mol Pharmacol"},{"issue":"2","key":"BF03256934_CR2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/ncpneph0076","volume":"2","author":"D. Choudhury","year":"2006","unstructured":"Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2006; 2(2): 80\u201391","journal-title":"Nat Clin Pract Nephrol"},{"issue":"2","key":"BF03256934_CR3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0272-6386(89)80130-1","volume":"13","author":"G.V. Warren","year":"1989","unstructured":"Warren GV, Korbet SM, Schwartz MM, et al. Minimal change glomerulopathy associated with nonsteroidal anti-inflammatory drugs. Am J Kidney Dis 1989; 13(2): 127\u201330","journal-title":"Am J Kidney Dis"},{"issue":"1Suppl.1","key":"BF03256934_CR4","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0272-6386(96)90570-3","volume":"28","author":"W.M. Bennett","year":"1996","unstructured":"Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996; 28(1 Suppl. 1): S56\u201362","journal-title":"Am J Kidney Dis"},{"issue":"5B","key":"BF03256934_CR5","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/S0002-9343(99)00113-8","volume":"106","author":"A. Whelton","year":"1999","unstructured":"Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106(5B): 13S\u201324S","journal-title":"Am J Med"},{"issue":"5","key":"BF03256934_CR6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5414\/CNP63381","volume":"63","author":"M. Almansori","year":"2005","unstructured":"Almansori M, Kovithavongs T, Qarni MU. Cyclooxygenase-2 inhibitor-associated minimal-change disease. Clin Nephrol 2005; 63(5): 381\u20134","journal-title":"Clin Nephrol"},{"issue":"5","key":"BF03256934_CR7","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/ajkd.2002.36349","volume":"40","author":"A.B. Alper Jr","year":"2002","unstructured":"Alper Jr AB, Meleg-Smith S, Krane NK. Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kidney Dis 2002; 40(5): 1086\u201390","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"BF03256934_CR8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/ndt\/gfh033","volume":"19","author":"U.C. Brewster","year":"2004","unstructured":"Brewster UC, Perazella MA. Acute tubulointerstitial nephritis associated with celecoxib. Nephrol Dial Transplant 2004; 19(4): 1017\u20138","journal-title":"Nephrol Dial Transplant"},{"issue":"9294","key":"BF03256934_CR9","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/S0140-6736(01)06745-9","volume":"358","author":"D. Demke","year":"2001","unstructured":"Demke D, Zhao S, Arellano FM. Interstitial nephritis associated with celecoxib. Lancet 2001; 358(9294): 1726\u20137","journal-title":"Lancet"},{"issue":"5","key":"BF03256934_CR10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.5414\/CNP63385","volume":"63","author":"J.B. Esteve","year":"2005","unstructured":"Esteve JB, Launay-Vacher V, Brocheriou I, et al. COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature. Clin Nephrol 2005; 63(5): 385\u20139","journal-title":"Clin Nephrol"},{"issue":"6","key":"BF03256934_CR11","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1053\/ajkd.2002.33412","volume":"39","author":"J. Henao","year":"2002","unstructured":"Henao J, Hisamuddin I, Nzerue CM, et al. Celecoxibinduced acute interstitial nephritis. Am J Kidney Dis 2002; 39(6): 1313\u20137","journal-title":"Am J Kidney Dis"},{"issue":"6591","key":"BF03256934_CR12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/bmj.295.6591.182","volume":"295","author":"G.D. Beun","year":"1987","unstructured":"Beun GD, Leunissen KM, Van Breda V, et al. Isolated minimal change nephropathy associated with diclofenac. Br Med J (Clin Res Ed) 1987; 295(6591): 182\u20133","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"2","key":"BF03256934_CR13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2125.1999.00869.x","volume":"47","author":"U. Ravnskov","year":"1999","unstructured":"Ravnskov U. Glomerular, tubular and interstitial nephritis associated with non-steroidal antiinflammatory drugs: evidence of a common mechanism. Br J Clin Pharmacol 1999; 47(2): 203\u201310","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"BF03256934_CR14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nrneph.2010.71","volume":"6","author":"M.A. Perazella","year":"2010","unstructured":"Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol 2010; 6(8): 461\u201370","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"BF03256934_CR15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00281-007-0094-z","volume":"29","author":"P.W. Mathieson","year":"2007","unstructured":"Mathieson PW. Minimal change nephropathy and focal segmental glomerulosclerosis. Semin Immunopathol 2007; 29(4): 415\u201326","journal-title":"Semin Immunopathol"},{"issue":"9","key":"BF03256934_CR16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2174\/138920009790711841","volume":"10","author":"J.A. Cornejo-Garcia","year":"2009","unstructured":"Cornejo-Garcia JA, Blanca-Lopez N, Dona I, et al. Hypersensitivity reactions to non-steroidal anti-inflammatory drugs. Curr Drug Metab 2009; 10(9): 971\u201380","journal-title":"Curr Drug Metab"},{"issue":"9272","key":"BF03256934_CR17","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/S0140-6736(00)05083-2","volume":"357","author":"J.L. Rocha","year":"2001","unstructured":"Rocha JL, Fernandez-Alonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet 2001; 357(9272): 1946\u20137","journal-title":"Lancet"},{"issue":"3","key":"BF03256934_CR18","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1053\/ajkd.2003.50146","volume":"41","author":"N. Alim","year":"2003","unstructured":"Alim N, Peterson L, Zimmerman SW, et al. Rofecoxibinduced acute interstitial nephritis. Am J Kidney Dis 2003; 41(3): 720\u20131","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"BF03256934_CR19","first-page":"182","volume":"17","author":"J. Quiralte","year":"2007","unstructured":"Quiralte J, Blanco C, Delgado J, et al. Challenge-based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory-drug-induced-reactions. J Investig Allergol Clin Immunol 2007; 17(3): 182\u20138","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"BF03256934_CR20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S1081-1206(10)61282-3","volume":"94","author":"M. Sanchez-Borges","year":"2005","unstructured":"Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol 2005; 94(1): 34\u20138","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"BF03256934_CR21","first-page":"215","volume":"36","author":"G. Senna","year":"2004","unstructured":"Senna G, Bilo MB, Antonicelli L, et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Eur Ann Allergy Clin Immunol 2004; 36(6): 215\u20138","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"27","key":"BF03256934_CR22","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.2174\/138161208786369740","volume":"14","author":"M. Viola","year":"2008","unstructured":"Viola M, Quaratino D, Gaeta F, et al. Cross-reactive reactions to nonsteroidal anti-inflammatory drugs. Curr Pharm Des 2008; 14(27): 2826\u201332","journal-title":"Curr Pharm Des"},{"issue":"4","key":"BF03256934_CR23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00403-007-0757-6","volume":"299","author":"T.B. Weberschock","year":"2007","unstructured":"Weberschock TB, Muller SM, Boehncke S, et al. Tolerance to coxibs in patients with intolerance to non-steroidal antiinflammatory drugs (NSAIDs): a systematic structured review of the literature. Arch Dermatol Res 2007; 299(4): 169\u201375","journal-title":"Arch Dermatol Res"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03256934.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03256934\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03256934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T01:24:14Z","timestamp":1558488254000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03256934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["BF03256934"],"URL":"https:\/\/doi.org\/10.1007\/bf03256934","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}